Renoprotective effects of dulaglutide in patients with T2DM and CKD

Research output: Contribution to journalComment/debateResearchpeer-review

The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

Original languageEnglish
JournalNature Reviews. Nephrology
Issue number11
Pages (from-to)659-660
Publication statusPublished - 2018

ID: 203862373